First Patient Dosed in MVP-S, KEYTRUDA Study for DLBCL

According to a news release from immuno-oncology company IMV Inc., the first patient has been dosed in the Phase 2b VITALIZE clinical trial. During the trial, researchers are evaluating a combination treatment of Merck’s KEYTRUDA and IMV’s maveropepimut-S (MVP-S) for people with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). As prior studies have shown potential benefits of MVP-S, researchers are hopeful that this will build upon this understanding.

Maveropepimut-S (MVP-S)

To begin, let’s first take a look at what maveropepimut-S (MVP-S) is. According to IMV:

The protein survivin is found in more than 15 types of solid tumor and hematologic cancers [and] plays a critical role in tumor biology as it is associated with tumor cell differentiation, proliferation, invasion and metastasis. We believe [MVP-S can] deliver a sustained flow of T cells that target survivin.

In prior studies, such as the SPiReL clinical trial, MVP-S, in conjunction with KEYTRUDA, was found to be relatively safe and well-tolerated. Additionally, there was a high response rate; sustained benefits; and quality-of-life (QOL) improvements. To learn more about those study findings, take a look here.

Within the Phase 2b VITALIZE trial, researchers will evaluate MVP-S and KEYTRUDA. Some patients will also receive the immune modulator cyclophosphamide, given orally, although researchers will also evaluate efficacy without cyclophosphamide. An estimated 150 patients will enroll.

About Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) exists under the larger umbrella of non-Hodgkin’s lymphoma (NHL). In fact, this highly malignant and aggressive cancer accounts for around 22% of NHL diagnoses. As the name suggests, DLBCL affects B-lymphocytes, a type of white blood cell. Risk factors of developing DLBCL include age (60+), having an autoimmune disease, a family history of DLBCL, or being immunocompromised. However, this cancer can affect people of any age. Symptoms associated with DLBCL include:

  • Drenching night sweats
  • Painless but swollen lymph nodes
  • Fever
  • Unintended weight loss
  • Itching
  • Abdominal pain (if cancer has spread to the abdomen)
  • Diarrhea (if cancer has spread to the abdomen)
Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Follow us